Metagenomi to Present at Upcoming Investor Conferences - Mar 24, 2022

• H.C. Wainwright Gene Therapy and Gene Editing Conference
  Virtual
  Date: Wednesday, March 30, 2022
  Time: A pre-recorded presentation will be available on-demand, starting at 7:00 a.m. ET
  Participant: Simon Harnest, Chief Investment Officer and SVP, Strategy, Metagenomi

• Goldman Sachs’ The New Guard: Privates Leading the Disruption in Healthcare
  In-person
  Date: Thursday, April 7, 2022
  Time: 10:00 a.m. ET
  Panel Title: Gene Editing: Moving from Molecular Scissors to Pencils
  Participants: Brian Thomas, PhD, CEO and Founder, Metagenomi; Simon Harnest, Chief Investment Officer and SVP, Strategy, Metagenomi

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005862/en/